Long-Term Outcomes After Neoadjuvant Pembrolizumab Based on Pathological Response in Patients With Resectable Stage III/IV Cutaneous Melanoma

You must be a member to content.

Already Have An Account? Log in Now

You can find your saved items on your dashboard, in the "saved" tab.

Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.

What does that mean?

1. Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
2. We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
3. Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.